Tumor-Agnostic AKT Inhibition: Is It Time to AKT?

IF 10.2 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-09-30 DOI:10.1158/1078-0432.ccr-25-2640

Ricardo Dahmer Tiecher,Alison M Schram

引用次数: 0

Abstract

Basket trials of AKT-mutated tumors show that pan-AKT inhibitors are active in hormone receptor-positive breast cancer. There is mounting evidence for AKT inhibition in other tumor types, although small sample sizes limit evaluation of the tumor-agnostic potential for AKT inhibition. Emerging AKT1 E17K-specific molecules may improve tolerability and efficacy.

查看原文本刊更多论文

与肿瘤无关的AKT抑制：是时候抑制AKT了吗？

对akt突变肿瘤的一揽子试验表明，泛akt抑制剂在激素受体阳性乳腺癌中具有活性。越来越多的证据表明AKT在其他类型的肿瘤中也有抑制作用，尽管小样本量限制了对AKT抑制的肿瘤不确定潜力的评估。新出现的AKT1 e17k特异性分子可能提高耐受性和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.